Selective activation of intracellular β1AR using a spatially restricted antagonist.

Autor:	Liccardo F; Cardiovascular Research Institute, University of California, San Francisco, USA., Morstein J; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, USA., Lin TY; Cardiovascular Research Institute, University of California, San Francisco, USA., Pampel J; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, USA., Shokat KM; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, USA.; Howard Hughes Medical Institute, University of California, San Francisco, USA., Irannejad R; Cardiovascular Research Institute, University of California, San Francisco, USA.; Department of Biochemistry & Biophysics, University of California, San Francisco, USA.
Jazyk:	angličtina
Zdroj:	BioRxiv : the preprint server for biology [bioRxiv] 2023 Nov 22. Date of Electronic Publication: 2023 Nov 22.
DOI:	10.1101/2023.11.22.568314
Abstrakt:	G-protein-coupled receptors (GPCRs) regulate several physiological and pathological processes and represent the target of approximately 30% of FDA-approved drugs. GPCR-mediated signaling was thought to occur exclusively at the plasma membrane. However, recent studies have unveiled their presence and function at subcellular membrane compartments. There is a growing interest in studying compartmentalized signaling of GPCRs. This requires development of novel tools to separate GPCRs signaling at the plasma membrane from the ones initiated at intracellular compartments. We took advantage of the structural and pharmacological information available for β1-adrenergic receptor (β1AR), an exemplary GPCR that functions at subcellular compartments, and rationally designed spatially restricted antagonists. We generated a cell impermeable β1AR antagonist by conjugating a suitable pharmacophore to a sulfonate-containing fluorophore. This cell-impermeable antagonist only inhibited β1AR on the plasma membrane. In contrast, a cell permeable β1AR agonist containing a non-sulfonated fluorophore, efficiently inhibited both the plasma membrane and Golgi pools of β1ARs. Furthermore, the cell impermeable antagonist selectively inhibited the phosphorylation of downstream effectors of PKA proximal to the plasma membrane in adult cardiomyocytes while β1AR intracellular pool remained active. Our tools offer promising avenues for investigating compartmentalized β1AR signaling in various context, potentially advancing our understanding of β1AR-mediated cellular responses in health and disease. They also offer a general strategy to study compartmentalized signaling for other GPCRs in various biological systems. Competing Interests: Competing interests K.M.S. has consulting agreements for the following companies, which involve monetary and/or stock compensation: Revolution Medicines, Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics, Erasca, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Mitokinin, Nested, Type6 Therapeutics, Venthera, Wellspring Biosciences (Araxes Pharma), Turning Point, Ikena, Initial Therapeutics, Vevo and BioTheryX.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu